Antitumour activity of water-soluble decovine in comparison with it's base decocine

Abstract

Aim of the study. To investigate the comparable value of acute toxicity and antitumor activity of new water soluble salt of decocine - preparation Decovine. Materials and methods. The study was carried out on 516 mice Balb/c, C57Bl6 or SHK without or with transplanted tumours AKATOL, AKATON, sarcoma S180, B16 and Ehrlih carcinoma (ACE). Decovine at the single doses of 50 or 75 mg/kg was administrated i.p. daily for 10 days; comparable drugs were administrated with well known schedules of treatment. All results were calculated with according to standard criterion: DL₅(MTD) and DL₅₀ or TGI and ILS. Sstatistically significant effects were calculated for p<0.05. Results. Decovine was low toxic for mice (MTD=230 mg/kg, DL50=417 mg/kg), and high effective against 3 from 5 strain of tumors AKATOL, AKATON and ACE at the same time by the developed tumors, TGI=56-98% or ILS=95% (p<0,05). In comparison of decocine, ^diamine or cyclophosphamide Decovine was on 20-30% more effective for TGI and in 3 times for ILS, especially by the treatment of developed tumor. Conclusion. New water soluble salt of decocine Decovine with comparable low toxicity and high antitumor activity can be considered as the candidate for clinical evaluation. This drug can be useful as for mono or combined chemotherapy.